Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Apramitha Innovations Private Limited operates in the Biotechnology & Pharmaceuticals technology area with a concentrated patent portfolio. There is currently 1 pending office action for the company, which is handled by PALENIK, JEFFREY T. This examiner is identified as the busiest examiner, managing the 1 busiest examiner pending action for the firm.
The prosecution activity is limited to 1 distinct art unit and 1 distinct examiner. This means the 1 pending office action is the sole focus of the company's current interactions with the USPTO. Because PALENIK, JEFFREY T is the only examiner involved, the prosecution path is highly centralized. The company's current patent strategy appears to be highly targeted within the biotechnology sector, necessitating a direct and efficient response.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALENIK, JEFFREY T | 1 | 53.6% | +27.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256733 | Apremilast Ophthalmic Compositions | PALENIK, JEFFREY T | 46d |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18256733 | Apremilast Ophthalmic Compositions | PALENIK, JEFFREY T | 1615 | §103 | Final Rejection | 46d | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial